Universidad Autónoma de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2016

  1. Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling

    Nature Medicine, Vol. 22, Núm. 1, pp. 91-96

2013

  1. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab)

    Cancer, Vol. 119, Núm. 9, pp. 1660-1668